Hepcidin mod 
Welcome,         Profile    Billing    Logout  
 7 Companies  5 Products   5 Products   18 Diseases   6 Trials   103 News 
13 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
sapablursen (IONIS-TMPRSS6-Lrx) / Ono Pharma
NCT04059406 / 2019-003505-96: Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx)

Terminated
2
29
Europe, RoW
sapablursen, ISIS 702843, IONIS TMPRSS6-LRx
Ionis Pharmaceuticals, Inc.
Beta Thalassemia Intermedia
03/23
03/23
NCT05143957 / 2021-003704-40: A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia Vera

Active, not recruiting
2
50
Europe, Canada, US, RoW
sapablursen, ISIS 702843, IONIS-TMPRSS6-LRx
Ionis Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc.
Phlebotomy Dependent Polycythemia Vera
06/25
06/26
rusfertide (PTG-300) / Protagonist Therap, Takeda
VERIFY, NCT05210790 / 2021-004732-29: A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera

Hourglass Mar 2025 - Mar 2025 : 32-week primary efficacy endpoint data from VERIFY study in PCV
Hourglass Jan 2024 - Mar 2024 : Q1'24 - Completion of enrollment of P3 VERIFY trial for PCV
Active, not recruiting
3
250
Europe, Canada, US, RoW
Placebo, Rusfertide
Protagonist Therapeutics, Inc.
Polycythemia Vera
02/25
06/25
THRIVE, NCT06033586: Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera

Enrolling by invitation
3
50
US
Open-label rusfertide
Protagonist Therapeutics, Inc.
Polycythemia Vera
04/26
04/27
PACIFIC, NCT04767802: PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit

Hourglass Dec 2023 - Dec 2023 : Data from PACIFIC trial for polycythemia vera at ASH 2023
Completed
2
20
RoW
PTG-300, Rusfertide
Protagonist Therapeutics, Inc.
Polycythemia Vera
03/23
03/23
REVIVE, NCT04057040: Hepcidin Mimetic in Patients With Polycythemia Vera

Hourglass Jan 2023 - Mar 2023 : Top-line data from REVIVE trial in patients with polycythemia vera
Active, not recruiting
2
80
US, RoW
PTG-300, Placebo
Protagonist Therapeutics, Inc.
Polycythemia Vera
10/25
01/26
DISC-0974 / Disc Medicine
NCT05320198: Study of DISC-0974 in Participants with Myelofibrosis or Myelodysplastic Syndrome and Anemia

Recruiting
1/2
150
US
DISC-0974
Disc Medicine, Inc
Myelofibrosis; Anemia, Anemia, Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera, Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Myelodysplastic Syndromes
09/26
09/26
DISC-0974-103, NCT05745883: Study of DISC-0974 to Assess the Safety, Tolerability, PK and PD of DISC-0974 in Participants with CKD and Anemia

Recruiting
1
50
US
DISC-0974, Placebo
Disc Medicine, Inc
Chronic Kidney Diseases, Anemia of Chronic Kidney Disease
09/25
05/26
DISC-3405 / Disc Medicine
NCT06985147: A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)

Not yet recruiting
2
20
NA
DISC-3405
Disc Medicine, Inc
Polycythemia Vera (PV)
02/27
02/29
NCT06389942: Single Ascending Dose Study of 9MW3011 in Chinese Healthy Subject

Completed
1
48
RoW
9MW3011, 9MW3011 placebo
Mabwell (Shanghai) Bioscience Co., Ltd.
Healthy
05/24
05/24
NCT06752746: A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia Vera

Recruiting
1
108
RoW
9MW3011
Mabwell (Shanghai) Bioscience Co., Ltd.
Polycythemia Vera
08/25
06/26
DISC-3405-101, NCT06050915: A Study of DISC-3405 in Healthy Volunteers

Completed
1
64
US
DISC-3405, 9MW3011, Placebo
Disc Medicine, Inc
Healthy Volunteer
07/24
07/24
NCT06772766: A Multiple Ascending Dose Study of 9MW3011 in Patients With Non-transfusion-dependent β-thalassemia

Recruiting
1
40
RoW
9MW3011, 9MW3011 placebo
Mabwell (Shanghai) Bioscience Co., Ltd.
Beta-Thalassemia
10/26
10/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
sapablursen (IONIS-TMPRSS6-Lrx) / Ono Pharma
NCT04059406 / 2019-003505-96: Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx)

Terminated
2
29
Europe, RoW
sapablursen, ISIS 702843, IONIS TMPRSS6-LRx
Ionis Pharmaceuticals, Inc.
Beta Thalassemia Intermedia
03/23
03/23
NCT05143957 / 2021-003704-40: A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia Vera

Active, not recruiting
2
50
Europe, Canada, US, RoW
sapablursen, ISIS 702843, IONIS-TMPRSS6-LRx
Ionis Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc.
Phlebotomy Dependent Polycythemia Vera
06/25
06/26
rusfertide (PTG-300) / Protagonist Therap, Takeda
VERIFY, NCT05210790 / 2021-004732-29: A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera

Hourglass Mar 2025 - Mar 2025 : 32-week primary efficacy endpoint data from VERIFY study in PCV
Hourglass Jan 2024 - Mar 2024 : Q1'24 - Completion of enrollment of P3 VERIFY trial for PCV
Active, not recruiting
3
250
Europe, Canada, US, RoW
Placebo, Rusfertide
Protagonist Therapeutics, Inc.
Polycythemia Vera
02/25
06/25
THRIVE, NCT06033586: Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera

Enrolling by invitation
3
50
US
Open-label rusfertide
Protagonist Therapeutics, Inc.
Polycythemia Vera
04/26
04/27
PACIFIC, NCT04767802: PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit

Hourglass Dec 2023 - Dec 2023 : Data from PACIFIC trial for polycythemia vera at ASH 2023
Completed
2
20
RoW
PTG-300, Rusfertide
Protagonist Therapeutics, Inc.
Polycythemia Vera
03/23
03/23
REVIVE, NCT04057040: Hepcidin Mimetic in Patients With Polycythemia Vera

Hourglass Jan 2023 - Mar 2023 : Top-line data from REVIVE trial in patients with polycythemia vera
Active, not recruiting
2
80
US, RoW
PTG-300, Placebo
Protagonist Therapeutics, Inc.
Polycythemia Vera
10/25
01/26
DISC-0974 / Disc Medicine
NCT05320198: Study of DISC-0974 in Participants with Myelofibrosis or Myelodysplastic Syndrome and Anemia

Recruiting
1/2
150
US
DISC-0974
Disc Medicine, Inc
Myelofibrosis; Anemia, Anemia, Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera, Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Myelodysplastic Syndromes
09/26
09/26
DISC-0974-103, NCT05745883: Study of DISC-0974 to Assess the Safety, Tolerability, PK and PD of DISC-0974 in Participants with CKD and Anemia

Recruiting
1
50
US
DISC-0974, Placebo
Disc Medicine, Inc
Chronic Kidney Diseases, Anemia of Chronic Kidney Disease
09/25
05/26
DISC-3405 / Disc Medicine
NCT06985147: A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)

Not yet recruiting
2
20
NA
DISC-3405
Disc Medicine, Inc
Polycythemia Vera (PV)
02/27
02/29
NCT06389942: Single Ascending Dose Study of 9MW3011 in Chinese Healthy Subject

Completed
1
48
RoW
9MW3011, 9MW3011 placebo
Mabwell (Shanghai) Bioscience Co., Ltd.
Healthy
05/24
05/24
NCT06752746: A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia Vera

Recruiting
1
108
RoW
9MW3011
Mabwell (Shanghai) Bioscience Co., Ltd.
Polycythemia Vera
08/25
06/26
DISC-3405-101, NCT06050915: A Study of DISC-3405 in Healthy Volunteers

Completed
1
64
US
DISC-3405, 9MW3011, Placebo
Disc Medicine, Inc
Healthy Volunteer
07/24
07/24
NCT06772766: A Multiple Ascending Dose Study of 9MW3011 in Patients With Non-transfusion-dependent β-thalassemia

Recruiting
1
40
RoW
9MW3011, 9MW3011 placebo
Mabwell (Shanghai) Bioscience Co., Ltd.
Beta-Thalassemia
10/26
10/26

Download Options